First Time Loading...
D

Decibel Therapeutics Inc
NASDAQ:DBTX

Watchlist Manager
Decibel Therapeutics Inc
NASDAQ:DBTX
Watchlist
Price: 4.91 USD Market Closed
Updated: Apr 24, 2024

Intrinsic Value

DBTX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. [ Read More ]

The intrinsic value of one DBTX stock under the Base Case scenario is 1.76 USD. Compared to the current market price of 4.91 USD, Decibel Therapeutics Inc is Overvalued by 64%.

Key Points:
DBTX Intrinsic Value
Base Case
1.76 USD
Overvaluation 64%
Intrinsic Value
Price
D
Worst Case
Base Case
Best Case

Valuation Backtest
Decibel Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DBTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Decibel Therapeutics Inc

Provide an overview of the primary business activities
of Decibel Therapeutics Inc.

What unique competitive advantages
does Decibel Therapeutics Inc hold over its rivals?

What risks and challenges
does Decibel Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Decibel Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Decibel Therapeutics Inc.

Provide P/S
for Decibel Therapeutics Inc.

Provide P/E
for Decibel Therapeutics Inc.

Provide P/OCF
for Decibel Therapeutics Inc.

Provide P/FCFE
for Decibel Therapeutics Inc.

Provide P/B
for Decibel Therapeutics Inc.

Provide EV/S
for Decibel Therapeutics Inc.

Provide EV/GP
for Decibel Therapeutics Inc.

Provide EV/EBITDA
for Decibel Therapeutics Inc.

Provide EV/EBIT
for Decibel Therapeutics Inc.

Provide EV/OCF
for Decibel Therapeutics Inc.

Provide EV/FCFF
for Decibel Therapeutics Inc.

Provide EV/IC
for Decibel Therapeutics Inc.

Show me price targets
for Decibel Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Decibel Therapeutics Inc?

How accurate were the past Revenue estimates
for Decibel Therapeutics Inc?

What are the Net Income projections
for Decibel Therapeutics Inc?

How accurate were the past Net Income estimates
for Decibel Therapeutics Inc?

What are the EPS projections
for Decibel Therapeutics Inc?

How accurate were the past EPS estimates
for Decibel Therapeutics Inc?

What are the EBIT projections
for Decibel Therapeutics Inc?

How accurate were the past EBIT estimates
for Decibel Therapeutics Inc?

Compare the revenue forecasts
for Decibel Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Decibel Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Decibel Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Decibel Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Decibel Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Decibel Therapeutics Inc with its peers.

Analyze the financial leverage
of Decibel Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Decibel Therapeutics Inc.

Provide ROE
for Decibel Therapeutics Inc.

Provide ROA
for Decibel Therapeutics Inc.

Provide ROIC
for Decibel Therapeutics Inc.

Provide ROCE
for Decibel Therapeutics Inc.

Provide Gross Margin
for Decibel Therapeutics Inc.

Provide Operating Margin
for Decibel Therapeutics Inc.

Provide Net Margin
for Decibel Therapeutics Inc.

Provide FCF Margin
for Decibel Therapeutics Inc.

Show all solvency ratios
for Decibel Therapeutics Inc.

Provide D/E Ratio
for Decibel Therapeutics Inc.

Provide D/A Ratio
for Decibel Therapeutics Inc.

Provide Interest Coverage Ratio
for Decibel Therapeutics Inc.

Provide Altman Z-Score Ratio
for Decibel Therapeutics Inc.

Provide Quick Ratio
for Decibel Therapeutics Inc.

Provide Current Ratio
for Decibel Therapeutics Inc.

Provide Cash Ratio
for Decibel Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Decibel Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Decibel Therapeutics Inc?

What is the current Free Cash Flow
of Decibel Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Decibel Therapeutics Inc.

Financials

Balance Sheet Decomposition
Decibel Therapeutics Inc

Current Assets 80.4m
Cash & Short-Term Investments 78.3m
Other Current Assets 2.1m
Non-Current Assets 13.9m
PP&E 13m
Other Non-Current Assets 934k
Current Liabilities 26.6m
Accounts Payable 617k
Accrued Liabilities 13.9m
Other Current Liabilities 12.1m
Non-Current Liabilities 14.5m
Long-Term Debt 46k
Other Non-Current Liabilities 14.5m
Efficiency

Earnings Waterfall
Decibel Therapeutics Inc

Revenue
0 USD
Operating Expenses
-66m USD
Operating Income
-66m USD
Other Expenses
2.6m USD
Net Income
-63.4m USD

Free Cash Flow Analysis
Decibel Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DBTX Profitability Score
Profitability Due Diligence

Decibel Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive 3-Year Average ROE
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
31/100
Profitability
Score

Decibel Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

DBTX Solvency Score
Solvency Due Diligence

Decibel Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
61/100
Solvency
Score

Decibel Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DBTX Price Targets Summary
Decibel Therapeutics Inc

Wall Street analysts forecast DBTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DBTX is 10 USD .

Lowest
Price Target
Not Available
Average
Price Target
10 USD
104% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DBTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DBTX Price
Decibel Therapeutics Inc

1M 1M
-
6M 6M
-
1Y 1Y
+58%
3Y 3Y
-49%
5Y 5Y
-73%
10Y 10Y
-73%
Annual Price Range
4.91
52w Low
2.76
52w High
5.23
Price Metrics
Average Annual Return -72.1%
Standard Deviation of Annual Returns
N/A
Max Drawdown -91%
Shares Statistics
Market Capitalization 123.4m USD
Shares Outstanding 25 126 900
Percentage of Shares Shorted 0.65%

DBTX Return Decomposition
Main factors of price return

What is price return decomposition?

DBTX News

Last Important Events
Decibel Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Decibel Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Decibel Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

123.4m USD

Dividend Yield

0%

Description

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Contact

MASSACHUSETTS
Boston
1325 Boylston Street, Suite 500
+16173708701.0
https://www.decibeltx.com/

IPO

2021-02-12

Employees

62

Officers

Pres, CEO & Director
Dr. Laurence E. Reid Ph.D.
Chief Devel. Officer
Mr. John J. Lee
Co-Founder & Member of Scientific Advisory Board
Dr. Albert S. B. Edge
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Mr. James B. Murphy
VP of Operations
Ms. Elaine Cope
Exec. VP & Chief People Officer
Ms. Anna Trask M.A.
Show More
Sr. VP of Discovery
Mr. Joe Burns Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one DBTX stock?

The intrinsic value of one DBTX stock under the Base Case scenario is 1.76 USD.

Is DBTX stock undervalued or overvalued?

Compared to the current market price of 4.91 USD, Decibel Therapeutics Inc is Overvalued by 64%.